Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.59 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | GRM1 | Q13255 | 11/20 | 0.52 |
| ▸ | GRM5 | P41594 | 11/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.48 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.48 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | QDPR | P09417 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548551 | 0.90 | NAMPT (0.59) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL31110456 | 0.88 | NAMPT (0.58) | NAMPTPDK4GRM1GRM5GPR119 | |
| SCHEMBL8912847 | 0.88 | NAMPT (0.63) | NAMPTPDK4GRM1GRM5GPR119 | |
| SCHEMBL18121785 | 0.87 | NAMPT (0.57) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL2951348 | 0.87 | NAMPT (0.60) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL29924834 | 0.87 | PDK4 (0.55) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL904049 | 0.86 | NAMPT (0.61) | NAMPTPDK4GRM1GRM5GPR119 | |
| SCHEMBL18253161 | 0.86 | NAMPT (0.62) | NAMPTPDK4GRM1GRM5CDK7 | |
| SCHEMBL31700404 | 0.86 | NAMPT (0.56) | NAMPTPDK4GRM1GRM5GPR119 | |
| SCHEMBL22324867 | 0.86 | MEN1 (0.57) | NAMPTPDK4GRM1GRM5CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507512-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | MERCK SHARP & DOHME LLC | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216764-A1 | Soluble Guanylate Cyclase Activators | GUCY1B1, GUCY1A1, GUCY1A2 | NAMPT 4227/4885PDK4 2382/4885GRM1 1758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.